Ibuprofen-induced hypersensitivity syndrome

Translational Research

Volumn 155, Issue 6, 2010, Pages 275-293

  Nanau, Radu M ^a   Neuman, Manuela G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALLOPURINOL; AMPICILLIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIULCER AGENT; ARACHIDONIC ACID; CHEMOKINE; CHLORMEZANONE; CLOFIBRIC ACID; CODEINE; COLESTIPOL; COLESTYRAMINE; CYTOKINE; IBUPROFEN; KETOROLAC; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PARACETAMOL; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; SULFONAMIDE; THROMBOXANE; ZIDOVUDINE;

ABDOMINAL PAIN; ACIDOSIS; AGING; AMINOTRANSFERASE BLOOD LEVEL; ANALGESIC ACTIVITY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BLISTER; BLOOD TOXICITY; BRONCHOSPASM; BURNING SENSATION; CHEILITIS; CHOLANGITIS; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CONJUNCTIVITIS; DEHYDRATION; DRESS SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG OVERDOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHILIA; ERYTHEMA; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; EYE PAIN; EYE TOXICITY; FATIGUE; FECES; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEADACHE; HEART DISEASE; HEART FAILURE; HEPATITIS; HEPATOSPLENOMEGALY; HUMAN; HYPERCHOLESTEROLEMIA; HYPOVOLEMIA; JAUNDICE; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; LABORATORY TEST; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; LUNG TOXICITY; MACULOPAPULAR RASH; MALAISE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PAIN; PANCREATITIS; PATIENT MONITORING; PLEURA EFFUSION; PRESCRIPTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS INHIBITION; PRURITUS; RETINITIS; REVIEW; RHEUMATIC DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SJOEGREN SYNDROME; SODIUM RETENTION; SORE THROAT; STEATORRHEA; STEATOSIS; STOMACH HEMORRHAGE; STOMATITIS; STRUCTURE ANALYSIS; T LYMPHOCYTE; THROMBOCYTE FUNCTION; URINE; URTICARIA; VOMITING; WATER RETENTION; WEAKNESS; XANTHOMATOSIS;

EID: 77952104767     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2010.01.005     Document Type: Review

References (126)

1. Browne G.S., Nelson C., Nguyen T., Ellis B.A., Day R.O., and Williams K.M. Stereoselective and substrate-dependent inhibition of hepatic mitochondrial β-oxidation and oxidative phosphorylation by the non-steroidal anti-inflammatory drugs Ibuprofen, Flurbiprofen, and Ketorolac. Biochem Pharmacol 57 (1999) 837-844
2. Müller S., Mayer J.M., Etter J.-C., and Testa B. Metabolic chiral inversion of Ibuprofen in isolated rat hepatocytes. Chirality 2 (1990) 74-78
3. Hamman M.A., Thompson G.A., and Hall S.D. Regioselective and stereoselective metabolism of Ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 54 (1997) 33-41
4. Freneaux E., Fromenty B., Berson A., et al. Stereoselective and nonstereoselective effects of Ibuprofen enantiomers on mitochondrial -oxidation of fatty acids. J Pharmacol Exp Ther 255 (1990) 529-535
5. Schettler T., Paris S., Pellett M., Kidner S., and Wilkinson D. Comparative pharmacokinetics of two fast-dissolving oral Ibuprofen formulations and a regular-release Ibuprofen tablet in healthy volunteers. Clin Drug Investig 21 (2001) 73-78
6. Rainsford K.D. History and development of Ibuprofen. In: Rainsford K.D. (Ed). Ibuprofen: a critical bibliographic review (1999), Taylor & Francis, Philadelphia, PA 1-24
7. Rainsford K.D. Pharmacology and toxicology of Ibuprofen. In: Rainsford K.D. (Ed). Ibuprofen: a critical bibliographic review (1999), Taylor & Francis, Philadelphia, PA 143-276
8. Halpern S.M., Fitzpatrick R., and Volans G.N. Ibuprofen toxicity. A review of adverse reactions and overdose. Adverse Drug React Toxicol Rev 12 (1993) 107-128
9. Rodríguez-González F.J., Montero J.L., Puente J., et al. Orthotopic liver transplantation after subacute liver failure induced by therapeutic doses of Ibuprofen. Am J Gastroenterol 97 (2002) 2476-2477
10. Al-Nasser I.A. Ibuprofen-induced liver mitochondrial permeability transition. Toxicol Lett 111 (2000) 213-218
11. Hall S.D., Rudy A.C., Knight P.M., and Brater D.C. Lack of presystemic inversion of (R)- to (S)- ibuprofen in humans. Clin Pharmacol Ther 53 (1993) 393-400
12. Mendes G.D., Mendes F.D., Domingues C.C., et al. Comparative bioavailability of three ibuprofen formulations in healthy human volunteers. Int J Clin Pharmacol Ther 46 (2008) 309-318
13. Martin W., Koselowske G., Töberich H., Kerkmann T.H., Mangold B., and Augustin J. Pharmacokinetics and absolute bioavailability of Ibuprofen after oral administration of Ibuprofen lysine in man. Biopharm Drug Dispos 11 (1990) 265-278
14. Lockwood G.F., Albert K.S., Gillespie W.R., et al. Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationship. Clin Pharmacol Ther 34 (1983) 97-103
15. Higton F. The pharmaceutics of Ibuprofen. In: Rainsford K.D. (Ed). Ibuprofen: a critical bibliographic review (1999), Taylor & Francis, Philadelphia, PA 53-86
16. Graham G.G., and Williams K.M. Metabolism and pharmacokinetics of Ibuprofen. In: Rainsford K.D. (Ed). Aspirin and related drugs (2004), Taylor & Francis, New York 157-180
17. Bramlage P., and Goldis A. Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers. BMC Pharmacol 8 (2008) 1471-1487
18. Doyle G., Furey S., Berlin R., et al. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther 13 (1999) 897-906
19. Wood D.M., Monaghan J., Streete P., Jones A.L., and Dargan P.I. Fatality after deliberate ingestion of sustained-release ibuprofen: a case report. Crit Care 10 (2006) R44
20. Wyeth Consumer Healthcare. Advil.com-Wyeth Consumer Healthcare. Available at: http://www.advil.com/products/advil/tablet_label.asp. Accessed August 27, 2009.
21. Endrenyi L. Pharmacokinetics: principles and clinical application. In: Kalant H., Grant D.M., and Mitchell J. (Eds). Principles of medical pharmacology. 7th ed (2007), Elsevier, Toronto, Canada 50-61
22. Mandal U., Das A., Agarwal S., et al. Bioequivalence study of two formulations containing 400 mg dexibuprofen in healthy Indian subjects. Arzneimittelforschung 58 (2008) 342-347
23. Endrenyi L. Pharmacokinetics. In: Kalant H., and Roschlau W.H.E. (Eds). Principles of medical pharmacology. 6th ed (1998), Oxford University Press, New York 55-66
24. Nielsen J.C., Bjerring P., Arendt-Nielsen L., and Petterson K.J. A double-blind, placebo controlled, cross-over comparison of the analgesic effect of ibuprofen 400 mg and 800 mg on laser-induced pain. Br J Clin Pharmacol 30 (1990) 711-715
25. Greenblatt D.J., Smith T.W., and Koch-Weser J. Bioavailability of drugs: the digoxin dilemma. In: Gibaldi M., and Prescott L. (Eds). Handbook of clinical pharmacokinetics (1983), ADIS Health Science Press, Balgowlah, Australia 1-24
26. In: Wagner J.G. (Ed). Pharmacokinetics for the pharmaceutical scientist (1993), Technomics Publishing Company, Lancaster, PA
27. Abernethy D.R., and Greenblatt D.J. Ibuprofen disposition in obese individuals. Arthritis Rheum 28 (1985) 1117-1121
28. In: Hardman J.G., and Limbird L.E. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed (2001), McGraw-Hill, New York 1966
29. Eller M.G., Wright III C., and Della-Coletta A.A. Absorption kinetics of rectally and orally administered ibuprofen. Biopharm Drug Dispos 10 (1989) 269-278
30. Zaffanello M., Brugnara M., Angeli S., and Cuzzolin L. Acute non-oliguric kidney failure and cholestatic hepatitis induced by Ibuprofen and Acetaminophen: a case report. Acta Pædiatr 98 (2009) 903-905
31. Evans A.M. Comparative pharmacology of S(+)-Ibuprofen and (RS)-Ibuprofen. Clin Rheumatol 1 (2001) S9-S14
32. Evans A.M., Nation R.L., Sansom L.N., Bochner F., and Somogyi A.A. The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. Biopharm Drug Dispos 11 (1990) 507-518
33. Garabedian-Ruffalo S.M., and Ruffalo R.L. Drug and nutrient interactions. Am Fam Physician 33 (1986) 165-174
34. Alam I., Ferrell L.D., and Bass N.M. Vanishing bile duct syndrome temporally associated with Ibuprofen use. Am J Gastroenterol 91 (1996) 1626-1630
35. Riley III T.R., and Smith J.P. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case study. Am J Gastroenterol 93 (1998) 1563-1565
36. Gasparetto P. Un caso di ittero epatocellulare in corso di trattamento con ibuprofen (A case of hepatocellular jaundice during treatment with ibuprofen). Minerva Pediatr 26 (1974) 531-533
37. Strassburg C.P., Strassburg A., Kneip S., et al. Development aspects of human hepatic drug glucuronidation in young children and adults. Gut 50 (2002) 259-265
38. Murray M.D., Brater D.C., Tierney W.M., Hui S.L., and McDonald C.J. Ibuprofen-associated renal impairment in a large general internal medicine practice. Am J Med Sci 299 (1990) 222-229
39. Friis H., and Andreasen P.B. Drug-induced hepatic injury: an analysis of 1100 cases reported to The Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 232 (1992) 133-138
40. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injury: A French population-based study. Hepatology 36 (2002) 451-455
41. Teoh N.C., and Farrell G.C. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis 7 (2003) 401-413
42. O'Connor N., Dargan P.I., and Jones A.L. Hepatocellular damage from non-steroidal anti-inflammatory drugs. Q J Med 96 (2003) 787-791
43. Brocks D.R., and Jamali F. The pharmacokinetics of Ibuprofen in humans and animals. In: Rainsford K.D. (Ed). Ibuprofen: A critical bibliographic review (1999), Taylor & Francis, Philadelphia, PA 87-142
44. Boelsteli U.A., Zimmerman H.J., and Kretz-Rommel A. Idisyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol 25 (1995) 207-235
45. Tigka E., Daskala I., Rallis G., Anagnostopoulou S., and Tesseromatis C. Adjuvant arthritis-induced changes on ampicillin binding in serum and tissue under the influence of non-steroidal anti-inflammatory drugs in rats. Eur J Drug Metab Pharmacokinet 30 (2005) 235-241
46. Fry S.W., and Seeff L.B. Hepatotoxicity of analgesic and antiinflammatory agents. Gastroenterol Clin N Am 24 (1990) 875-885
47. Wood D.M., Monaghan J., Streete P., Jones A.L., and Dargan P.I. Fatality after deliberate ingestion of sustained-release ibuprofen: a case report. Crit Care 10 (2006) R44
48. Senekjian H.O., Lee C.S., Kuo T.H., Au D.S., and Krothapalli R. Absorption and disposition of ibuprofen in hemodialyzed uremic patients. Eur J Rheumatol Inflamm 6 (1983) 155-162
49. Antal E.J., Wright III C.E., Brown B.L., Albert K.S., Aman L.C., and Levin N.W. The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites. J Clin Pharmacol 26 (1986) 184-190
50. Zimmerman H.J. Update of hepatotoxicity due to classes of drugs in common clinical use: non-steroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin Liver Dis 10 (1990) 322-338
51. Menzel S., Waibel R., Brune K., and Geisslinger G. Is the formation of R-ibuprofenyl-adenylate the first stereoselective step of chiral inversion?. Biochem Pharmacol 48 (1994) 1056-1058
52. Zheng C., Hao H., Wang G., et al. Chiral separation of ibuprofen and chiral pharmacokinetics in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet 33 (2008) 45-51
53. Chen C.Y., Lu P.H., and Chen C.S. Metabolic inversion of stereoisomeric Ibuprofen in man. J Formos Med Assoc 90 (1991) 437-442
54. Desai NS, Johnston GS. Toxicity, nonsteroidal anti-inflammatory agents: eMedicine emergency medicine. Available at: http://emedicine.medscape.com/article/816117. Accessed August 29, 2009.
55. Tracy T.S., and Hall S.D. Metabolic inversion of (R)-Ibuprofen: epimerization and hydrolysis of ibuprofenyl-coenzyme A. Drug Metab Dispos 20 (1992) 322-327
56. Kirchheiner J., Meineke I., Freytag G., Meisel C., Roots I., and Brockmöller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 72 (2002) 62-75
57. Jamali F., and Kunz-Dober C.M. Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. Br J Clin Pharmacol 47 (1999) 391-396
58. Evans A.M. Pharmacodynamics and pharmacokinetics of the Profens: enantioselectivity, clinical implications, and special reference to S(+)-Ibuprofen. J Clin Pharmacol 36 (1996) 7S-15S
59. Nichol K.J. The medicinal chemistry of Ibuprofen. In: Rainsford K.D. (Ed). Ibuprofen: a critical bibliographic review (1999), Taylor & Francis, Philadelphia, PA 25-52
60. Leemann T.D., Transon C., Bonnabry P., and Dayer P. A major role for cytochrome P450TB(CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 19 (1993) 189-195
61. Chen C.Y., and Chen C.S. Stereoselective disposition of Ibuprofen in patients with renal dysfunction. The J Pharmacol Exp Ther 268 (1994) 590-594
62. Tulaganov A.A., Volchenok V.I., Kukes V.G., and Arzamastsev A.P. Clinical pharmacokinetics of Ibuprofen. J Med Pharm Chem 27 (1993) 21-24
63. Chen C.Y., and Chen C.S. Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics. J Clin Pharmacol 40 (1995) 67-72
64. Schmitt M., and Guentert T.W. Effect of age on the pharmacokinetics of Tenoxicam in comparison to other non-steroidal anti-inflammatory drugs (NSAIDS). Scand J Rheumatol Suppl 18 (1989) 86-89
65. Kotlyar M., and Carson S.W. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 37 (1999) 8-19
66. Bowdle T.A., Neal G.D., Levy R.H., and Heimbach D.M. Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients. J Pharmacol Exp Ther 213 (1980) 97-99
67. Petric M., Tasic L., and Sukljevic S. Nonsteroidal anti-inflammatory drug usage and gastrointestinal outcomes in the Republic of Serbia. J Pain Palliat Care Pharmacother 23 (2009) 40-47
68. Neuman M.G., Malkiewicz I.M., and Shear N.H. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndrome. Clin Biochem 33 (2000) 517-524
69. Hall A.H., Smolinske S.C., Conrad F.L., et al. Ibuprofen overdose: 126 cases. Ann Emerg Med 15 (1986) 1308-1313
70. Öker E.E., Hermann L., Baum C.R., Fentzke K.M., Sigg T., and Leikin J.B. Serious toxicity in a young child due to Ibuprofen. Acad Emerg Med 7 (2000) 821-823
71. Downie A., Ali A., and Bell D. Severe metabolic acidosis complicating massive ibuprofen overdose. Postgrad Med J 69 (1993) 575-577
72. Seifert S.A., Bronstein A.C., and McGuire T. Massive Ibuprofen ingestion with survival. J Toxicol Clin Toxicol 38 (2000) 55-57
73. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 23 (1995) 16-24
74. Krivoy N., Taeri M., and Neuman M.G. Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf 1 (2006) 289-299
75. Neuman M.G., and Nicar M. Apoptosis in ibuprofen-induced Stevens-Johnson syndrome. Trans Res 149 (2007) 254-259
76. Neuman M.G., Shear N.H., Malkiewicz I.M., et al. Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides. Trans Res 149 (2007) 243-253
77. Srivastava M., Perez-Atayde A., and Jonas M.M. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson Syndromes in a child. Gastroenterology 115 (1998) 743-746
78. Chung W.H., Hung S.I., and Chen Y.T. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 7 (2007) 317-323
79. Roujeau J.C., Kelly J.P., Naldi L., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 (1995) 1600-1607
80. Halevy S., Ghislain P.D., Mockenhaupt M., et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58 (2008) 25-32
81. Mockenhaupt M., Viboud C., Dunant A., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128 (2008) 35-44
82. Posadas S.J., and Pichler W.J. Delayed drug hypersensitivity reactions-new concepts. Clin Exp Allergy 37 (2007) 989-999
83. Jurima-Romet M., Crawford K., and Huang H.S. Comparative cytotoxicity of non-steroidal anti-inflammatory drugs in primary cultures of rat hepatocytes. Toxicol In Vitro 8 (1994) 55-66
84. Leeder J.S., Cannon M., Nakhooda A., and Spielberg S.P. Drug metabolite toxicity assessed in human lymphocytes with a purified, reconstituted cytochrome P450 system. J Pharmacol Exp Ther 245 (1988) 956-962
85. Beeler A., Engler O., Gerber B.O., and Pichler W.J. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 117 (2006) 455-462
86. Vassalli P. The pathophisiology of tumor necrosis factors. Annu Rev Immunol 10 (1992) 411-452
87. Ertel W., Morrison M.H., Ayala A., and Chaudry I.H. Eicosanoids regulate tumor necrosis factor synthesis after hemorrhage in vitro and in vivo. J Trauma 31 (1991) 609-616
88. Wanner G.A., Müller P., Ertel W., Busch C.J., Menger M.D., and Messmer K. Differential effect of cyclooxygenase metabolites on proinflammatory cytokine release by Kupffer cells after liver ischemia and reperfusion. Am J Surg 175 (1998) 146-151
89. Mascagni P., Sabbatini V., Biordi L., et al. R- and S-isomers of nonsteroidal anti-inflammatory drugs differentially regulate cytokine production. Eur Cytokine Netw 11 (2000) 185-192
90. Chitturi S., and George J. Hepatotoxicity of commonly used drugs: monsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, phychotropic drugs. Semin Liver Dis 22 (2002) 169-183
91. Castell J.V., Larrauri L., and Gómez-Lechón M.J. A study of relative hepatotoxicity in vitro of the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen and butibufen. Xenobiotica 18 (1988) 737-745
92. Rabinovitz M., and Van Thiel D.H. Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 87 (1992) 1696-1704
93. Walker A.M. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal anti-inflammatory drugs. Arthritis Rheum 40 (1997) 201-208
94. Rodríguez L.A.G., Williams R., Derby L.E., Dean A.D., and Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 154 (1994) 311-316
95. Turner W.M. The Food and Drug Administration algorithm special workshop -regulatory. Drug Inf J 18 (1984) 259-266
96. Shear N.H. Diagnosing cutaneous adverse reactions to drugs. Arch Dermatol 126 (1990) 94-97
97. Bravo J.F., Jacobson M.P., and Mertens B.F. Fatty liver and pleural effusion with Ibuprofen therapy. Ann Intern Med 87 (1977) 200-201
98. Stempel D.A., and Miller J.J. Lymphopenia and hepatic toxicity with ibuprofen. J Pediatr 90 (1977) 657-658
99. Laurent S., Rahier J., Geubel A.P., Lerut J., and Horsmans Y. Subfulminant hepatitis requiring liver transplantation following ibuprofen overdose. Liver 20 (2000) 93-94
100. Taghian M., Tran T.A., Bresson-Hadni S., Menget A., Felix S., and Jacquemin E. Acute vanishing bile duct syndrome after Ibuprofen therapy in a child. J Pediatr 145 (2004) 273-276
101. Sternleib P., and Robinson R.M. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. NY State J Med 87 (1978) 200-202
102. Lee C.Y., and Finkler A. Acute intoxication due to ibuprofen overdose. Arch Pathol Lab Med 110 (1986) 747
103. Borel I., Hedelius F., Baumgartner C., Vial T., Scoazec J.Y., and Dumortier J. Severe acute hepatitis associated with ibuprofen treatment. Gastroentérol Clin Biol 25 (2001) 430
104. Reinicke C., and Klinger W. Influence of ibuprofen on drug-metabolizing enzymes in rat liver in vivo and in vitro. Biochem Pharmacol 24 (1975) 145-147
105. Bendele A.M., Hulman J.F., White S., Brodhecker C., and Bendele R.A. Hepatocellular proliferation in Ibuprofen-treated mice. Toxicol Pathol 21 (1993) 15-20
106. Rekka E., Ayalogu E.O., Lewis D.F.V., Gibson G.G., and Ioannides C. Induction of hepatic microsomal CYP4A activity and of peroxisomal -oxidation by two non-steroidal anti-inflammatory drugs. Arch Toxicol 68 (1994) 73-78
107. Sternlieb P., and Robinson R.M. Stevens-Johnson Syndrome plus toxic hepatitis due to Ibuprofen. NY State J Med 78 (1978) 1239-1243
108. Chitturi S., and Farrell G.C. Drug-induced cholestasis. Semin Gastrointest Dis 12 (2001) 113-124
109. Morelli M.S., and O'Brien F.X. Stevens-Johnson Syndrome and cholestatic hepatitis. Dig Dis Sci 46 (2001) 2385-2388
110. Hurwitz R.M., Rivera H.P., Gooch M.H., Stama T.G., Handt A., and Weiss J. Toxic shock syndrome or toxic epidermal necrolysis? Case reports showing clinical similarity and histologic separation. J Am Acad Dermatol 7 (1982) 246-254
111. Neuman M.G., Monteiro M., and Rehm J. Drug interactions between psychoactive Substances and antiretroviral therapy in individuals infected with human immunodeficiency and Hepatitis viruses. Subst Use Misuse 41 (2006) 1395-1463
112. Neuman M.G., Peng P., and Betschel S.D. Immune mediated drug hypersensitivity reactions to hydromorphone. Eur J Dermatol 18 (2008) 250
113. Neuman M.G., Shear N.H., Gomez M., et al. Cytokines-chemokines and hypersensitivity syndrome reactions to ibuprofen. Eur J Dermatol 18 (2008) 269-270
114. Lonjou C., Thomas L., Borot N., et al. A marker for Stevens-Johnson syndrome- ethnicity matters. Pharmacogenomics J 6 (2006) 265-268
115. Dore J., and Salisbury R.E. Morbidity and mortality of mucocutaneous diseases in the pediatric population at a tertiary care center. J Burn Care Res 28 (2007) 865-870
116. *0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 143 (2007) 367-368
117. Layton D., Marshal V., Boshier A., Friedmann P., and Shakir S.A.W. Serious skin reactions andselective COX-2 inhibitors: A case series from prescription-event monitoring in England. Drug Saf 29 (2006) 687-696
118. Neuman M.G., Shear N., Gomez M., et al. Hypersensitivity reaction to Ibuprofen. Ther Drug Monit 31 (2009) 5,77,626
119. Yoshimura T., Kurita C., Hayata M., and Nagai H. Diagnosis of drug allergy by the lymphocyte stimulation test with the MTT [3-(4,5-dimethyl thiazol-2-yl)-2,5-diophenyl tetrazolium bromide] assay. Biol Pharm Bull 16 (1993) 686-689
120. Chissov V.I., Sviridova I.K., Sergeeva N.S., et al. In vitro study of matrix surface properties of porous granulated calcium phosphate ceramic materials made in Russia. Bull Exp Biol Med 145 (2008) 499-503
121. Berns M., Toennessen M., Koehne P., Altmann R., and Obladen M. Ibuprofen augments bilirubin toxicity in rat cortical neuronal culture. Pediatr Res 65 (2009) 392-396
122. Nassif A., Moslehi H., Le Gouvello S., et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 123 (2004) 850-855
123. McElwee N.E., Veltri J.C., Bradford D.C., and Rollins D.E. A prospective, population-based study of acute ibuprofen overdose: complications are rare and routine serum levels not warranted. Ann Emerg Med 19 (1990) 657-662
124. Al-Meshal M.A., El-Sayed Y.M., Al-Balla S.R., and Gouda M.W. The effect of Colestipol and Cholestyramine on Ibuprofen bioavailability in man. Biopharm Drug Dispos 15 (1994) 463-471
125. Knights K.M., Addinall T.F., and Roberts B.J. Enhanced chiral inversion of R-ibuprofen in liver from rats treated with clofibric acid. Biochem Pharmacol 41 (1991) 1775-1777
126. Solomon D.H., and Goodson N.J. The cardiovascular system in rheumatic disease: the newest "extraarticular" manifestation?. J Rheumatol 32 (2005) 1415-1419